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Summary
Epimerase-deficiency galactosemia results from impair-
ment of the human enzyme UDP-galactose-4-epimerase
(hGALE). We and others have identified substitution
mutations in the hGALE alleles of patients with the clin-
ically mild, peripheral form of epimerase deficiency. We
report here the first identification of an hGALEmutation
in a patient with the clinically severe, generalized form
of epimerase deficiency. The mutation, V94M, was
found on both GALE alleles of this patient. This same
mutation also was found in the homozygous state in two
additional patients with generalized epimerase defi-
ciency. The specific activity of the V94M-hGALE protein
expressed in yeast was severely reduced with regard to
UDP-galactose and partially reduced with regard to
UDP-N-acetylgalactosamine. In contrast, two GALE-
variant proteins associated with peripheral epimerase de-
ficiency, L313M-hGALE and D103G-hGALE, demon-
strated near-normal levels of activity with regard to both
substrates, but a third allele, G90E-hGALE, demon-
strated little, if any, detectable activity, despite near-
normal abundance. G90E originally was identified in a
heterozygous patient whose other allele remains un-
characterized. Thermal lability and protease-sensitivity
studies demonstrated compromised stability in all of the
partially active mutant enzymes.
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Introduction
Epimerase-deficiency galactosemia (MIM 230350) re-
sults from impairment of the human enzyme UDP-
galactose-4-epimerase (hGALE; E.C.5.1.3.2), which
normally catalyzes the third step in the Leloir pathway
of galactose metabolism (Segal and Berry 1995), as well
as the interconversion of UDP-N-acetylgalactosamine
(UDP-GalNAc) and UDP-N-acetylglucosamine (UDP-
GlcNAc) (Maley and Maley 1959; Piller et al. 1983;
Kingsley et al. 1986a). Historically, two forms of this
autosomal recessive disorder have been distinguished:
the first is termed “peripheral,” because patients exhibit
enzyme deficiency that is restricted to the circulating
blood cells, and the second is termed “generalized,” be-
cause patients exhibit epimerase deficiency in all tissues
tested. The peripheral form of epimerase deficiency is
considered to be clinically benign (Segal and Berry 1995)
and can be quite common in some ethnic groups (Alano
et al. 1997). In contrast, only five patients with gener-
alized epimerase deficiency have been reported; all have
shown poor growth and learning difficulties, among
other complications, despite a galactose-restricted diet
(Walter et al., in press). Finally, a unique patient, iden-
tified by newborn screening, who remained clinically
well in infancy, despite a normal diet, but who later
demonstrated significant developmental delays and was
shown to have only partial epimerase activity in his cells
was described recently (Quimby et al. 1997; Alano et
al. 1998). The molecular basis of the distinction between
these various forms of epimerase deficiency remains un-
known and is addressed by the experiments reported
here.
The first clues to a potential explanationwere revealed
120 years ago when Mitchell et al. (1975) reported the
reversal of hGALE deficiency in cultures of leukocytes
and lymphocytes derived from patients with the periph-
eral form of the disorder. These authors noted that stim-
ulation of patient cells, with phytohemagglutinin, re-
sulted in epimerase-activity levels close to those observed
in controls. Transformation of the patient cells to create
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long-term lymphoblast lines also resulted in essentially
normal epimerase activity. A comparison of the prop-
erties of hGALE derived from patient lymphoblasts ver-
sus that derived from controls revealed similarMichaelis
kinetic (Km) values and electrophoretic mobilities but
increased heat sensitivity in the patient-derived samples.
These authors concluded that either an increased rate of
synthesis of a mutant enzyme or derepression of an ad-
ditional epimerase locus in the cultured cells might ac-
count for their observations. The results reported in this
article strongly favor the first possibility.
The human cDNA and gene encoding hGALE were
cloned and sequenced recently by Daude et al. (1995)
and by Maceratesi et al. (1998). The availability of these
sequences has enabled the characterization, by us and
others, of hGALE alleles derived from patients with
epimerase-deficiency galactosemia. Seven such muta-
tions—N34S, G90E, D103G, L183P, K257R, L313M,
and G319E—all derived from patients with peripheral
(Maceratesi et al. 1998) or near-peripheral epimerase-
deficiency galactosemia (Quimby et al. 1997; Alano et
al. 1998), have been reported to date.
We report here the first identification of an hGALE
mutation, V94M, derived from a patient with the severe,
generalized form of epimerase-deficiency galactosemia.
Subsequent testing of samples from two additional gen-
eralized epimerase-deficiency patients, who are believed
to be unrelated to the first proband, revealed that both
patients also were homozygous for V94M. We used a
yeast expression system for the human enzyme to char-
acterize both this mutant allele and others derived from
patients with peripheral epimerase deficiency, to address
the question of whether there is a molecular/biochemical
distinction between the hGALE alleles associated with
the two reported forms of epimerase-deficiency galac-
tosemia. Our results, combined with those reported else-
where, suggest that some naturally occurring hGALE
substitution mutations result in severe catalytic impair-
ment, whereas others have little effect on enzyme func-
tion. The functionally mild mutations, however, result
in partial enzyme destabilization that may cause GALE
activity to fall below the threshold of detection in qui-
escent cells, such as those in the circulating blood, lead-
ing to the observed absence of GALE activity in these
cells. The three patients with generalized epimerase-
deficiency described here are the only individuals ge-
notyped to date who each carry two mutant alleles of
GALE that demonstrate severe catalytic impairment.
Patients, Material, and Methods
Patients
The proband originally studied was the product of a
consanguineous marriage and has been described else-
where (Holton et al. 1981; Henderson andHolton 1983;
Walter et al., in press). She presented at age 5 d with
symptoms of classic galactosemia, including vomiting,
hypotonia, jaundice, galactosuria, and hepatomegaly.
Enzyme activities of galactose-1-phosphate uridylyl-
transferase and galactokinase were found to be within
the normal range. However, hGALE activity was defi-
cient both in erythrocytes and in cultured skin fibro-
blasts. Clinical follow-up at age 19 mo confirmed that,
even while on a galactose-restricted diet, the child re-
mained hypotonic, with an enlarged spleen and devel-
opmental delay (Henderson and Holton 1983). Later in
life she was noted to have nerve deafness and moderate
learning difficulties, but there was no evidence of ovarian
dysfunction (Holton 1990; Walter et al., in press). The
other two patients tested (patients 4 and 5 in the report
by Walter et al. [in press]) were first cousins from an
extended consanguineous family not known to be re-
lated to the first patient. One of these two additional
patients is the sibling of another generalized epimerase-
deficiency patient, described elsewhere (Sardharwalla et
al. 1988).
Reverse Transcription–PCR Amplification and Analysis
of hGALE cDNA and Genomic DNA
Total RNA was isolated from cultured fibroblast cells
from the proband and her parents, as described else-
where (Fridovich-Keil et al. 1991). First-strand cDNA
synthesis was performed by use of GIBCO Superscript
II RNase H reverse transcriptase, according to the
manufacturer’s recommendations. Then, the cDNA tem-
plate was amplified by PCR with three sets of primers:
HEPIMF2 (5′-GCCGGAATTCATAAAAATGGCAG-
AGAAGGTGCTGG-3′) and HEPIM5R (5′-CGATG-
AAGAACTTGGACTTGC-3′), HEPIM6F (5′-GGAA-
CGTAGTGCTGCTGCGC-3 ′) and HEPIM11R2
(5 ′-CTGCTTTTCCTGGTCCTTGGTAG-3 ′), and
HEPIM4F (5′-GGACCATCCAGCTTCTGG-3′) and
HEPIM9R (5′-CCAGAGGCCTTCTCCATAGCC-3′).
Independently amplified samples were sequenced di-
rectly by use of the Big Dye kit (Perkin Elmer), as rec-
ommended by the manufacturer. Genomic confirmation
of the identified mutation was accomplished as described
in Results, by use of primers HEPIMF3 (5′-GCGGCG-
GGTCCAGGAGCTGAC-3′) and HEPIMR6 (5′-TCC-
TCACCAATGCAGCCAGAGGC-3′).
Yeast Strains, Plasmids, and Expression Studies
All recombinant DNA manipulations were performed
according to standard techniques (Sambrook et al. 1989)
and by use of Escherichia coli strain XL1-Blue (Strata-
gene). The yeast strain used was yBBQ1 (MATa gal80
gal10-120 ura3-52 his3-200 ade2-101 lys2-801 tyr1-
501) (Quimby et al. 1997). All mutant hGALE alleles
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expressed in yeast were recreated from the wild-type
sequence, by use of the Stratagene QuickChange site-
directed mutagenesis kit, and the resultant clones were
confirmed by dideoxy sequencing. All hGALE alleles to
be transformed into yeast were subcloned into the low-
copy-number expression plasmids pBQy1 and pBQy4
(Quimby et al. 1997). All yeast transformations, culture
manipulations, and extract preparations were performed
according to standard protocols, as described elsewhere
(Fridovich-Keil 1995a, 1995b; Elsevier et al. 1996;
Quimby et al. 1997).
GALE-Activity Assays
GALE activity was evaluated in yeast extracts by de-
termination of the conversion of UDP-galactose (UDP-
gal) to UDP-glucose (UDP-glc) or of UDP-GalNAc to
UDP-GlcNAc. With regard to the first substrate, assays
were performed essentially as described elsewhere
(Quimby et al. 1997). In brief, each 25-ml reaction con-
tained, except where otherwise noted, 5 ml premix (0.06
mM [0.1 mCi] 14C-UDP-gal; Amersham CFB129, 2 mM
[unlabeled] UDP-gal, 0.2 M glycine buffer [pH 8.7]), 5
ml 20-mM NAD, and 15 ml yeast extract diluted in lysis
buffer (20 mM HEPES/KOH [pH 7.5], 1 mM DTT, and
0.3 mg BSA/ml). With regard to the second substrate,
assays were performed as above, except that each 25-ml
reaction contained 8.75 ml premix (209 mM [0.1 mCi]
14C-UDP-GalNAc, 28.6 mM pyruvate, and 286 mM gly-
cine [pH 8.7]), 5 ml 20-mM NAD, and 11.25 ml yeast
extract diluted in lysis buffer. All reactions were incu-
bated at 37C for 30 min, were stopped by boiling for
10 min, and then were centrifuged in a microfuge on
high speed for 10 min, at room temperature, to pellet
insoluble material. Finally, 10 ml of each supernatantwas
spotted onto a prewashed, predried PEI-cellulose thin-
layer chromatography (TLC) plate (Baker) and was
dried in an incubator at 37C for 30 min. The chro-
matogram was run in a single dimension, for 16–24 h,
with a solvent of 1.5 mM Na2B4O7, 5 mM H3BO3, and
25% ethylene glycol. Paper toweling was clipped at the
top of each TLC plate, to extend the effective run time
of each assay. After chromatography, each plate was
removed from the solvent and air dried. Areas containing
radioactive material were visualized and quantitated by
use of a BioRad phosphorimager. Because a low level of
background signal that did not increase with load and
that was not visible as a spot was nonetheless detected,
by the phosphorimager, in the “product” range of each
negative control lane, this signal was subtracted from
all other values, prior to calculation of the activity levels
plotted.
Trypsin Cleavage Assay
Each reaction included 80 mg soluble yeast lysate and
40 ng trypsin (GIBCO 1#), incubated in a total volume
of 100 ml at 30C for 0, 2.5, 5, 10, 15, 20, 25, or 30
min. Reactions were stopped by boiling (5 min) in 1#
sample buffer (2% SDS, 10% sucrose, 62.5 mM Tris
[pH 6.8], 15.5 mg DTT/ml, and bromophenol blue) and
then were subjected to PAGE followed by western blot
analysis with the anti-hGALE polyclonal antiserum
EU69, as described below. Comparison of two indepen-
dent analyses confirmed the reproducibility of the results
obtained.
Western Blot Analysis
Western blot analyses were performed essentially
as described elsewhere (Fridovich-Keil et al. 1995b);
hGALE was detected by use of a rabbit polyclonal an-
tiserum (EU69) raised against purified hexahistidine-
tagged human epimerase protein. EU69 was used at a
dilution of 1:40,000. To control for loading of lanes, a
rabbit polyclonal antiserum generated against yeast cy-
clophilin A (Zydowsky et al. 1992) also was included,
at a dilution of 1:30,000. The secondary antibody used
was a donkey anti–rabbit Ig coupled to horseradish per-
oxidase (Amersham). Signals were visualized by use of
the enhanced chemiluminescence (ECL) kit (Amersham)
and were quantitated by use of a Molecular Dynamics
Personal Densitometer SI scanning laser densitometer.
Results
Pedigree Analysis and Identification of the V94M
Substitution
Direct sequencing of cDNA samples PCR amplified
from the proband and both parents revealed a GrA
transition at position 269 (downstream of the start co-
don), resulting in the predicted amino acid substitution
of methionine for valine at residue 94 (V94M). The mu-
tation was detected in the homozygous state in the child
and in the heterozygous state in both parents, which is
consistent with the consanguineous history of the family.
Because this substitution fortuitously created a NcoI re-
striction site, it was easily confirmed in genomic DNA,
as illustrated in figure 1. In brief, a 1.6-kb fragment that
spanned the relevant region and included a second, con-
stitutive NcoI site was PCR amplified from genomic
DNA of the child, both parents, and two unrelated con-
trols.NcoI digestion of the wild-type sequence, followed
by agarose-gel electrophoresis, yielded bands at 1.3 kb
and 0.3 kb (fig. 1, unblackened arrows), whereas diges-
tion of the mutant sequence yielded bands at 0.8 kb and
0.5 kb (fig. 1, blackened arrows) and at 0.3 kb. Results
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Figure 1 Confirmation of the G269A mutation in genomic DNA. A, Diagram indicating positions of constitutive (unblackened arrows)
and mutation-specific (blackened arrow) NcoI restriction sites within a PCR-amplified fragment. B, Ethidium bromide–stained agarose gel
demonstrating fragment sizes obtained by PCR amplification and NcoI digestion of genomic DNA from both parents, the patient, and two
unrelated controls. Marker band sizes, in kilobases, are indicated to the left. Unblackened arrows to the right indicate wild-type bands, and
blackened arrows to the right indicate mutation-specific bands.
of the genomic analysis were fully consistent with the
cDNA-sequencing results.
Two additional samples of genomic DNA, represent-
ing two other patients with generalized epimerase defi-
ciency (patients 4 and 5 in the report by Walter et al.
[in press]), also were tested as described above (data not
shown). Both demonstrated NcoI cleavage patterns that
were indistinguishable from those of the original pro-
band. Direct sequencing of PCR products, representing
the appropriate regions from both of these patients, fur-
ther confirmed the presence of the G269A mutation (en-
coding the V94M substitution) in the homozygous state
in both patients (data not shown).
Expression of Wild-Type and Mutant Alleles of hGALE
in the Homozygous State in Yeast
To probe the functional impact of V94M on hGALE,
we recreated this substitution by site-directed mutagen-
esis of the otherwise wild-type sequence (see Patients,
Material, and Methods) and expressed the encoded
protein from a low-copy-number centromeric (CEN)
plasmid in a null-background strain of yeast, yBBQ1
(Quimby et al. 1997). To facilitate a comparison of the
biochemical properties of this mutant protein with those
of others representing patients with peripheral epimerase
deficiency, we also recreated and expressed three addi-
tional mutant alleles, G90E-, D103G-, and L313M-
hGALE (Maceratesi et al. 1998).
As a first test of the ability of the mutant hGALE
proteins to function in yeast, strains of yBBQ1 express-
ing each protein were assayed for growth on synthetic
medium containing galactose as the sole carbon source.
As illustrated in figure 2, cultures of cells expressing
L313M-hGALE or D103G-hGALE grew indistinguish-
ably from cells expressing wild-type hGALE. In contrast,
cells expressing V94M-hGALE grew poorly, and cells
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Figure 2 Growth curves of yBBQ1 yeast expressing the indicated
alleles of hGALE cultured in medium containing galactose as the sole
carbon source. Each point plotted represents the average  SD of
three cultures.
Figure 3 Activity and abundance of wild-type and mutant
hGALE enzymes expressed in yeast. Top, Conversion of UDP-gal to
UDP-glc detected in crude lysates of yeast expressing each of the in-
dicated hGALE alleles in the homozygous state ( ). Middle, Av-n  3
erage activity values from the top panel divided by average abundance
(estimated by densitometric analysis of three independent western
blots), normalized to wild-type. Bottom, Representative western blot
analyses of lysates probed with antisera that detect hGALE and yeast
cyclophilin (an endogenous control for loading).
expressing G90E-hGALE did not grow any better than
those from the negative control, which expressed no
hGALE. All cultures grew well on medium containing
glucose as the carbon source (data not shown).
As a further test of the functional capacity of the sub-
stituted hGALE proteins, crude lysates of cells expressing
each protein were assayed, relative to positive and neg-
ative controls, for activity with respect to UDP-gal, as
described in Patients, Material, and Methods. As illus-
trated in figure 3 (top panel), both D103G-hGALE and
L313M-hGALE extracts demonstrated near-normal ac-
tivity, whereas both G90E-hGALE and V94M-hGALE
extracts demonstrated little, if any, detectable activity.
These results were fully consistent with the growth
curves described above. Western blot analyses of each
extract, with a rabbit polyclonal antiserum against
hGALE, further demonstrated that all the mutant pro-
teins exhibited essentially normal levels of abundance.
A second antiserum, which detected an endogenous
yeast protein, cyclophilin, was included to control for
loading of lanes. Estimates of activity, adjusted for small
differences in abundance (fig. 3, middle panel), again
indicated that both D103G-hGALE and L313M-hGALE
remained largely active, whereas bothG90E-hGALEand
V94M-hGALE did not.
Impact of NAD on Mutant hGALE Proteins Expressed
in Yeast
Previous studies of another patient allele, N34S-
hGALE, which exhibited ∼70% wild-type levels of ac-
tivity under standard in vitro conditions (Quimby et al.
1997), demonstrated that activity was restored to wild-
type levels when increased exogenous NAD was added.
We therefore tested activity in duplicate extracts repre-
senting wild-type, D103G-hGALE, and L313M-hGALE
proteins, under a range of exogenous NAD concentra-
tions; all six samples demonstrated indistinguishable
profiles as a function of NAD (data not shown). There-
fore, excess exogenous NAD did not rescue full activity
from these substituted hGALE proteins, indicating allele
specificity of the N34S-hGALE result.
Activity of Wild-type and Mutant hGALE Proteins, with
Respect to UDP-GalNAc
As an additional test of the functional capacity of each
substituted hGALE enzyme, assays were performed by
use of UDP-GalNAc as substrate. Extracts of cells ex-
pressing wild-type hGALE converted UDP-GalNAc to
UDP-GlcNAc, at a rate of 4.83 nmoles/mg protein/min
(table 1). As had been seen for the UDP-gal studies,
extracts of cells expressing both D103G-hGALE and
L313M-hGALE demonstrated near-normal activity,
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Figure 4 Conversion of UDP-gal to UDP-glc detected in crude
lysates of yeast expressing each of the indicated combinations of
hGALE alleles ( ).n  3
Figure 5 Impact of temperature on activity of wild-type and
mutant hGALE enzymes. Assays were performed on crude lysates of
yeast expressing each of the hGALE alleles indicated. Values plotted
represent averages  SD ( ).n  3
whereas extracts of cells expressing G90E-hGALE ex-
hibited no activity. In contrast, however, extracts of cells
expressing V94M-hGALE, which exhibited only 5% ac-
tivity with respect to UDP-gal, exhibited 24% activity
when challenged with UDP-GalNAc. Clearly, not all mu-
tations impacted both activities equally.
Expression of Mutant Alleles of hGALE in the
Heterozygous State in Yeast
In an effort to uncover potential allelic interactions,
such as those reported elsewhere (Quimby et al. 1997),
each hGALE mutant allele characterized above also was
expressed in yeast in the heterozygous state, together
with the wild-type sequence. As illustrated in figure 4,
extracts both of D103G-hGALE/wild-type cells and
of L313M-hGALE/wild-type cells demonstrated near-
normal levels of activity (90% and 94% wild type,
respectively), whereas extracts both of G90E-hGALE/
wild-type cells and of V94M-hGALE/wild-type cells
demonstrated approximately half-normal levels of ac-
tivity (47% and 43%wild type, respectively). Therefore,
no clear evidence of either partial dominant negative or
partial dominant positive interaction involving these al-
leles was observed.
Studies of Enzyme Stability
We addressed the question of hGALE enzyme stability
by using two approaches: the first measured wild-type
and mutant enzyme activities as a function of temper-
ature, and the second measured wild-type and mutant
protein sensitivities to trypsin digestion as a function of
time. As illustrated in figure 5, extracts of cells expressing
both D103G-hGALE and L313M-hGALE were mark-
edly more sensitive than wild-type cells to temperatures
150C. Indeed, at 53C both mutant enzymes were al-
most completely inactive, whereas the wild-type enzyme
still demonstrated near-maximal activity. With regard to
trypsin digestion, one mutant protein (L313M-hGALE)
exhibited essentially wild-type resistance, one (V94M-
hGALE) exhibited more than wild-type resistance,
and two (G90E-hGALE and D103G-hGALE) exhibited
markedly compromised resistance (figure 6). Although
neither test mimics the actual conditions in a circulating
red blood cell, these data together suggest that the pro-
teins encoded by all the tested patient-derived hGALE
alleles were either severely impaired (e.g., V94M and
G90E) or, by at least some measure, less stable than the
wild-type protein.
Discussion
The results reported here demonstrate two major
points. First, structural substitutionmutations in hGALE
can associate with generalized epimerase-deficiency ga-
lactosemia as well as with the peripheral form of the
disease. This observation is in contrast with the sugges-
tion of Maceratesi et al. (1998), who identified five sub-
stitution mutations in the DNA of patients with periph-
eral epimerase deficiency and who hypothesized that
mutations outside the coding region of hGALE that im-
pact gene expression might explain the difference be-
tween the peripheral and generalized forms of the dis-
ease. Although as-yet-unidentified regulatory mutations
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Table 1
Activity of Wild-Type and Substituted hGALE
Proteins, with Respect to UDP-GalNAc
hGALE Allele
Activity Level (%)a
[nmoles UDP-GlcNAc/
mg protein/min]
Wild-type 4.83  .24 (100)
G90E .00  .05 (0)
V94M 1.14  .12 (24)
D103G 3.36  .12 (70)
L313M 5.63  .56 (117)
No GALE .00  .02 (0)
a Values are average  SD ( ).n  3
Figure 6 Trypsin cleavage of wild-type and mutant hGALE pro-
teins. Yeast lysates prepared from cells expressing the indicated alleles
of hGALE were incubated with trypsin for the times indicated and
then were subjected to western blot analysis as described in Patients,
Material, and Methods.
may exist in some patients, the data reported here dem-
onstrate that regulatory mutations are not required to
explain the distinction between the two recognized forms
of epimerase-deficiency galactosemia.
The second major point reported here concerns the
“other” epimerase reaction normally catalyzed by
hGALE, namely, the interconversion of UDP-GalNAc
and UDP-GlcNAc. In view of the key roles played by
these compounds in the assembly of complex polysac-
charides and other glycosylated macromolecules, espe-
cially in the brain, the impact of patient mutations on
this reaction may be as, if not more, relevant for the
pathogenesis of epimerase-deficiency galactosemia as is
the interruption of the Leloir pathway. Our results (fig.
3 and table 1) clearly demonstrate that some patient
mutations (e.g., G90E and D103G) disrupt hGALE ac-
tivity equally, with respect to both substrates, whereas
others do not. For example, in our study, V94M-hGALE
exhibited only 5% activity with respect to UDP-gal but
24% activity with respect to UDP-GalNAc. Interestingly,
in studies of fibroblasts from the original proband,
Kingsley et al. (1986b) detected 1.8% wild-type activity
by using UDP-gal as substrate and 11.6% activity by
using UDP-GalNAc as substrate. The clinical outcome
for this patient might have been even more severe if she
had not retained this significant level of activity with
respect to UDP-GalNAc. Although all the substituted
proteins tested here exhibited activity toward UDP-
GalNAc that was equal to or greater than the activity
that they exhibited toward UDP-gal, it seems reasonable
to assume that this may not be a general rule. Other
naturally occurring patient alleles may encode substi-
tuted proteins that function well in the Leloir pathway
but that are impaired in their interconversion of UDP-
GalNAc and UDP-GlcNAc. Since many clinical labs cur-
rently test only the conversion of UDP-gal to UDP-glc,
these patients might not be detected.
Allelic Interaction
Previously, we studied a compound heterozygous pa-
tient with epimerase deficiency whose alleles demon-
strated partial dominant negative interactions both with
wild-type hGALE and with each other (Quimby et al.
1997). We saw no evidence of such allelic interaction
with the four alleles in this study, suggesting that these
interactions are allele specific and may represent the ex-
ception rather than the rule for naturally occurring mu-
tations in hGALE.
Structural Studies
In an effort to understand the structural distinction
between hGALE substitutions resulting in severe versus
mild enzymatic impairment, we homology mapped each
of the mutations studied to the E. coli GALE (eGALE)
crystal structure (coordinate set 1KVQ, Brookhaven
Protein Data Bank [Thoden et al. 1997]). Our results
suggested potential explanations for at least some of the
experimental data obtained. For example, hGALE res-
idue V94 corresponds with eGALE residue V86, which
is predicted to lie in a loop near the core of the enzyme,
∼5 A˚ from the bound-substrate sugar ring. Although
substitution of methionine for valine at that position
caused no obvious steric problems, the longer side chain
on the methionine may disrupt either interactions with
the substrate or the local protein structure needed for
efficient catalysis. hGALE residue G90 corresponds to
eGALE residue G82, which forms part of a b-strand,
near the core of the protein, that is surrounded by NAD
on three sides. The substitution of a glutamic acid for a
neutral glycine would put a negative charge in themiddle
of the protein, perhaps disrupting the structural integrity
of the protein, if not it’s ability to interact with NAD.
hGALE residue D103 corresponds to eGALEE95,which
is predicted to make a salt bridge with lysine 92 (K92).
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Since the hGALE residue corresponding to eGALE K92
is also a lysine (K100), one might predict that aspartic
acid 103 in hGALE also normally participates in a salt
bridge; clearly, substitution of a glycine (D103G) for the
natural acidic residue would be predicted to disrupt this
interaction. Finally, hGALE residue L313 corresponds
to eGALE residue K305, which is predicted to lie in a
short a-helix near the outside surface of the protein. The
structural impact of the substitution of a methionine at
this position in the human protein remains unclear.
Genotypes and Phenotypes
The data reported here demonstrate that all three pa-
tients with generalized epimerase deficiency who were
tested are homozygotes for the same mutation, V94M,
despite the fact that they currently are believed to orig-
inate from two unrelated families. Furthermore, two of
these three are the siblings of the only other two patients
with generalized epimerase deficiency reported to date
(Walter et al., in press). By extrapolation, we therefore
can conclude that all five reported patients with gener-
alized epimerase-deficiency galactosemia must be ho-
mozygotes for the same mutation. Whether future cases
of unrelated patients with this disorder also will carry
V94M remains to be seen.
Perhaps the two most clinically relevant questions
raised by this study, as well as by our previous report
(Quimby et al. 1997), are (1) whether epimerase-defi-
ciency galactosemia is clinically a binary disorder or a
continuum and (2) whether a genotype-phenotype pat-
tern is emerging. In view of the small number of patients
genotyped and the lack of long-term follow-up data for
the overwhelming majority of patients currently cate-
gorized as having the peripheral form of the disorder,
these questions cannot be answered at present. However,
even from the small number of patient alleles now bio-
chemically characterized, it is clear that some mutations
appear to be mild and others severe and that these mu-
tations do not assort neatly along clinical lines. Themost
severe allele modeled to date is G90E, which was iden-
tified originally in a heterozygous patient ostensibly with
peripheral epimerase deficiency (Maceratesi et al. 1998).
We can only hypothesize that the other allele in this
patient must retain significant activity. Since most pa-
tients with peripheral epimerase deficiency either are
never diagnosed or are lost to follow-up very early in
life, we also cannot rule out the possibility that even
these patients may not be truly asymptomatic. For ex-
ample, at least some of these patients may be at increased
risk for cataracts (Endres and Shin 1990; Jakobs et al.
1990; Schulpis et al. 1993). Furthermore, the possibility
of other later-onset complications is reinforced by the
observation that clinical symptoms were not apparent
in the ostensibly peripheral compound heterozygous pa-
tient, reported elsewhere (Quimby et al. 1997; Alano
et al. 1998), until he was 11 year old. Clearly, further
studies will be required, to reveal the true genetic, bio-
chemical, and clinical spectrum of epimerase-deficiency
galactosemia.
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